Oppenheimer Starts Ocugen, Inc. (OCGN) at Outperform

Oppenheimer analyst Leland Gershell initiates coverage on Ocugen, Inc. (NASDAQ: OCGN) with a Outperform rating and a price target of $10.00.

The analyst comments "We view Ocugen as an emerging gene therapy leader in blinding ocular disorders. Lead asset OCU400 is in Phase 3 for retinitis pigmentosa (RP, ~100K in US), for which a potential 2027 approval could provide near-term entry into a sizable and poorly-met rare disease market opportunity. Programs for two other progressively degenerative retinal diseases, Stargardt (~30K in US) and geographic atrophy (GA, >1M in US), are not far behind—mgmt. anticipates three FDA applications over the next three years—and offer upside in markets where current standards of care have limitations in efficacy, durability, and treatment burden. The company's one-and-done candidates differentiate from genetic replacement or editing approaches that struggle with disease-wide scalability. Next up: full Phase 2 GA data this month. Initiate at Outperform, $10 PT."

For an analyst ratings summary and ratings history on Ocugen, Inc. click here. For more ratings news on Ocugen, Inc. click here.

Shares of Ocugen, Inc. closed at $1.77 yesterday.

You May Also Be Interested In

• Carlyle to sell Copia Power to EQT - FT
• Horizon Quantum Holdings (HQ) spreader of 1560 contracts of November 25 and 45 calls
• Ionis Pharmaceuticals (IONS) PT Lowered to $100 at Citi